We are live on ! Find out more
GLMD icon

Galmed Pharmaceuticals
GLMD

18 hedge funds and large institutions have $25M invested in Galmed Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 3

118% more capital invested

Capital invested by funds: $11.4M → $25M (+$13.5M)

100% more funds holding

Funds holding: 9 → 18 (+9)

0.01% more ownership

Funds ownership: 0.01% → 0.01% (+0.01%)

Holders
18
Holders Change
+9
Holders Change %
+100%
% of All Funds
0.41%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
3
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NCM
Nantahala Capital Management
Connecticut
+$3.29M
2
SFM
Sphera Funds Management
Israel
+$1.95M
3
6CM
683 Capital Management
New York
+$827K
4
JGC
J. Goldman & Co
New York
+$508K
5
Morgan Stanley
Morgan Stanley
New York
+$378K

Top Sellers

Rank Fund Capital Flow
1
GL
GLG LLC
New York
-$1.36M
2
SKK
Shepherd Kaplan Krochuk
Massachusetts
-$167K
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$57K

GLMD Hedge Fund Activity: Q4 2017 in Review

18 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q4 2017, worth a combined $25M — up 118% from $11.4M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new GLMD positions and 3 closed out — a net gain of 9 holders — while 3 added to existing stakes and 0 trimmed.

The largest buyer was Nantahala Capital Management, opening a new position worth an estimated $3.29M. The largest seller was GLG LLC, exiting entirely with an estimated $1.36M sold.

  • 18 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q4 2017, up from 9 in Q3 2017.
  • Funds reported $25M of Galmed Pharmaceuticals stock for Q4 2017, up 118% quarter-over-quarter.
  • 12 funds opened new Galmed Pharmaceuticals positions in Q4 2017 and 3 closed out, a net change of +9 holders.
  • The largest Galmed Pharmaceuticals buyer in Q4 2017 was Nantahala Capital Management, an estimated $3.29M added.
  • The largest Galmed Pharmaceuticals seller in Q4 2017 was GLG LLC, an estimated $1.36M sold.

Based on aggregated 13F filings for Q4 2017.